It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The maintenance of genomic stability during the cell cycle of progenitor cells is essential for the faithful transmission of genetic information. Mutations in genes that ensure genome stability lead to human developmental syndromes. Mutations in Ataxia Telangiectasia and Rad3-related (ATR) or in ATR-interacting protein (ATRIP) lead to Seckel syndrome, which is characterized by developmental malformations and short life expectancy. While the roles of ATR in replicative stress response and chromosomal segregation are well established, it is unknown how ATRIP contributes to maintaining genomic stability in progenitor cells in vivo. Here, we generated the first mouse model to investigate ATRIP function. Conditional inactivation of Atrip in progenitor cells of the CNS and eye led to microcephaly, microphthalmia and postnatal lethality. To understand the mechanisms underlying these malformations, we used lens progenitor cells as a model and found that ATRIP loss promotes replicative stress and TP53-dependent cell death. Trp53 inactivation in Atrip-deficient progenitor cells rescued apoptosis, but increased mitotic DNA damage and mitotic defects. Our findings demonstrate an essential role of ATRIP in preventing DNA damage accumulation during unchallenged replication.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Universidade Federal do Rio de Janeiro, Programa de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Rio de Janeiro, Brazil (GRID:grid.8536.8) (ISNI:0000 0001 2294 473X); Université Paris-Descartes, Equipe Labellisée Ligue Contre le Cancer, Institut Cochin, INSERM U1016, UMR8104 CNRS, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
2 German Cancer Research Center (DKFZ), Clinical Cooperation Unit Neuropathology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Jena, Germany (GRID:grid.418245.e) (ISNI:0000 0000 9999 5706)
3 Université Paris-Descartes, Equipe Labellisée Ligue Contre le Cancer, Institut Cochin, INSERM U1016, UMR8104 CNRS, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
4 University Medical Center of the Johannes Gutenberg University Mainz, Institute of Toxicology, Mainz, Germany (GRID:grid.410607.4)
5 Universidade Federal do Rio de Janeiro, Programa de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Rio de Janeiro, Brazil (GRID:grid.8536.8) (ISNI:0000 0001 2294 473X)